ATXI (Avenue Therapeutics, Inc.) רווח נקי למניה ב-12 החודשים האחרונים

The lack of consistent revenue due to the clinical testing stage of Avenue Therapeutics (ATXI) highlights the current level of rolling earnings per share, where 24.69 describes the current status of the metric. Patents for stationary analgesics serve as a defense, creating a barrier to entry. However, the risk of FDA application rejections impacts the ecosystem and the loyalty of investors awaiting the approval of new CNS drugs.
Avenue Therapeutics, Inc (ATXI) - פילוחי מדדים ודוחות פיננסיים

Avenue Therapeutics focuses on the long-term expansion of its drug portfolio for treating neurological pathologies. Clinical trial expenses directly impact the bottom line, which currently stands at 24.69. This metric reflects the portion of net income per share annually, excluding the impact of issuance volume. Investors use it to assess the efficiency of the business's capitalization. By analyzing the rolling net income per share, one can track the dynamics of the company's transformation.